Combination of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter Inhibitors in Type 1 Diabetes: Why, when and How? An Exploration of the Rationale and Clinical Scenarios for Combining These 2 Adjunctive Agents

Endocrinology & Metabolism Clinics of North America · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles